Jan A van Noord

Summary

Affiliation: Atrium Medical Centre
Country: The Netherlands

Publications

  1. ncbi Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
    J A Van Noord
    Dept of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Eur Respir J 26:214-22. 2005
  2. ncbi Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Chest 129:509-17. 2006
  3. ncbi The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients
    J A Van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
    Respir Med 103:22-9. 2009
  4. ncbi Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms
    J A Van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Respir Med 104:995-1004. 2010
  5. ncbi QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
    Thorax 65:1086-91. 2010
  6. ncbi 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD
    J A Van Noord
    Dept of Respiratory Diseases, Atrium Medisch Centrum, The Netherlands
    Pulm Pharmacol Ther 24:666-72. 2011
  7. ncbi Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
    Anthony D'Urzo
    Department of Family and Community Medicine DFCM, University of Toronto, Ontario, Canada
    Respir Res 12:156. 2011

Collaborators

Detail Information

Publications7

  1. ncbi Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
    J A Van Noord
    Dept of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Eur Respir J 26:214-22. 2005
    ..i.d. A combination of both drugs q.d. was most effective and provided an additive effect throughout the 24-h dosing interval...
  2. ncbi Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Chest 129:509-17. 2006
    ..The combination of short-acting beta(2)-agonists and anticholinergics in the treatment of COPD has been well documented, but data on combination of long-acting agents are lacking...
  3. ncbi The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients
    J A Van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
    Respir Med 103:22-9. 2009
    ..The Respimat Soft Mist Inhaler (SMI), a novel, propellant-free inhaler, has been developed and proposed as an alternative delivery device for use with tiotropium...
  4. ncbi Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms
    J A Van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Respir Med 104:995-1004. 2010
    ..Clinical information on 24-h spirometric efficacy of combining tiotropium and salmeterol compared to single-agent therapy is lacking in patients with COPD...
  5. ncbi QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
    Thorax 65:1086-91. 2010
    ....
  6. ncbi 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD
    J A Van Noord
    Dept of Respiratory Diseases, Atrium Medisch Centrum, The Netherlands
    Pulm Pharmacol Ther 24:666-72. 2011
    ..Olodaterol is a novel long-acting β(2)-adrenoceptor agonist with a pre-clinical profile that suggests 24-h bronchodilation may be achieved with once-daily administration...
  7. ncbi Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
    Anthony D'Urzo
    Department of Family and Community Medicine DFCM, University of Toronto, Ontario, Canada
    Respir Res 12:156. 2011
    ..The glycopyrronium bromide in COPD airways clinical study 1 (GLOW1) evaluated the efficacy, safety and tolerability of NVA237 in patients with moderate-to-severe COPD...